Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder

Area of Science:

• Urology
• Molecular Biology
• Oncology

Background:

• Bladder pathologies significantly impact the quality of life, especially in the elderly.
• Current treatments for bladder diseases require novel therapeutic targets.
• Rho GTPase Rac1 is frequently dysregulated and overexpressed in various bladder pathologies.

Purpose of the Study:

• To analyze the roles of Rac1 in diverse bladder pathologies, including infections, diabetes-induced dysfunction, and cancers.
• To investigate Rac1's contribution to bladder cancer progression, metastasis, and epithelial-mesenchymal transition.
• To explore the therapeutic potential of small molecule Rac1 inhibitors for bladder diseases.

Main Methods:

• Analysis of Rac1's involvement in tumorigenesis and metastasis of bladder cancer cells.
• Evaluation of small molecules (e.g., NSC23766, EHT 1864) targeting Rac1.
• Discussion of Rac1 inhibitor interaction sites (GTP binding and GEF interaction sites).

Main Results:

• Rac1 plays a significant role in bladder cancer development and progression.
• Specific small molecules targeting Rac1 demonstrate efficacy against bladder cancer.
• Rac1 inhibitors offer a potential strategy for managing bladder dysfunction and lower urinary tract symptoms.

Conclusions:

• Targeting Rac1 with small molecules presents a promising therapeutic avenue for various bladder pathologies.
• Rac1 inhibition may help combat bladder dysfunction, improve symptoms, and treat advanced prostate cancer with reduced bladder side effects.
• Further research into Rac1-targeted approaches could lead to better management of age-related bladder conditions.